252 results about "Plasma cell" patented technology

The invention relates to antibodies or antibody fragments that bind CD269 (BCMA), thereby disrupting the interaction between CD269 and its native ligands (BAFF and APRIL), and their use in the treatment of plasma cell-mediated diseases such as multiple myeloma and autoimmune diseases.

The invention relates to antibodies, and antigen binding fragments thereof, that bind to hemagglutinin and neutralize a group 1 subtype and a group 2 subtype of influenza A virus. The invention also relates to nucleic acids that encode, immortalized B cells and cultured single plasma cells that produce, and to epitopes that bind to such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, treatment and prevention of influenza A virus infection.

The present invention relates to methods and compositions for the diagnosis, treatment, management, or prevention of plasma cell disorders, including systemic light-chain amyloidosis (AL) and multiple myeloma (MM). In particular, the invention encompasses the use of anti-CD32B antibodies, analogs, derivatives or fragments thereof, or compounds or agents that bind to CD32B and modulate CD32B activity in the plasma cells of mammals. The invention also encompasses the use of anti-CD32B antibodies, analogs, derivatives or fragments thereof, or CD32B binding compounds or agents in combination with or in addition to other cancer therapies for the treatment, prevention, management, or amelioration of a plasma cell disorder characterized by the expression of CD32B, or one or more symptoms thereof. The invention further relates to the use of anti-CD32B antibodies, analogs, derivatives or fragments thereof for the detection of aberrant or altered expression of CD32B in plasma cells, to diagnosis and/or characterize a plasma cell disorder.

The subject invention concerns methods and materials for diagnosing, monitoring the progress, and/or providing a prognosis for multiple myeloma and other conditions associated with antibody production in a person or animal. The methods o f the invention utilize mass spectrometry for quantitative monitoring and detection of antibody produced by the plasma cells. The methods of the invention can be utilized for diagnosis, monitoring, and/or prognosis of multiple myeloma, monoclonal gammopathy, and other immunological or hematological conditions and disorders. In addition to detecting and quantifying antibody in a sample, other biological markers, such as serum albumin and/or beta-2-microglobulin, can also be detected and quantified using the present invention, and in combination with detection and quantification of antibody. Thus, in one embodiment, both antibody and serum albumin and/or beta-2-microglobulin are detected and quantified using mass spectrometry and a diagnosis or prognosis made based on the results and levels detected.

The present invention provides a chimeric antigen receptor (CAR) comprising: (i) a B cell maturation antigen (BCMA)-binding domain which comprises at least part of a proliferation-inducing ligand (APRIL); (ii) a spacer domain (iii) a transmembrane domain; and (iv) an intracellular T cell signaling domain. The invention also provides the use of such a T-cell expressing such a CAR in the treatment of plasma-cell mediated diseases, such as multiple myeloma.

The invention relates to gene engineering and antibody preparation and specifically discloses a preparation method and application of a high-throughput fully-humanized antibody. The preparation methodcomprises the following steps: separating peripheral blood monouclear cells; separating single cells of plasma cells or antigen-specificity memory B blymphocytes; amplifying the heavy-chain and light-chain gene variable regions of single B cell antibody by use of a primer provided by the inventor; establishing an expression system containing antibody heavy-chain and light-chain genes by use of alinear expression system containing a heavy-chain fragment or light-chain fragment constant area; finally, separating and purifying a fully humanized monoclonal antibody. By adopting the primer combination provided by the invention to amplify the genes in the antibody heavy-chain and light-chain variable areas, natural pairing of the light-chain and heavy-chain variable areas can be maintained, and the preparation method has the advantages of high gene diversity, high titer, full humanization, high antibody affinity, strong specificity, no heterologous serum reaction, no risk of propagating other infectious diseases, etc.

To identify molecular determinants of lytic bone disease in multiple myeloma, the expression profiles of ˜12,000 genes in CD138-enriched plasma cells from newly diagnosed multiple myeloma patients exhibiting no radiological evidence of lytic lesions (n=28) were compared to those with ≧3 lytic lesions (n=47). Two secreted WNT signaling antagonists, soluble frizzled related protein 3 (SFRP-3/FRZB) and the human homologue of Dickkopf-1 (DKK1), were expressed in 40 of 47 with lytic bone lesions, but only 16 of 28 lacking bone lesions (P<0.05). DKK1 and FRZB were not expressed in plasma cells from 45 normal bone marrow donors or 10 Waldenstrom's macroglobulinemia, a related plasma cells malignancy that lacks bone disease. These data indicate that these factors are important mediators of multiple myeloma bone disease, and inhibitors of these proteins may be used to block bone disease.

Methods for reducing the number of pathologic antibody producing B cells in a patient suffering from an autoimmune disease by administration of an anti-germline antibody are described. Methods for removing pathologic antibodies and B cells and plasma cells producing pathologic antibodies from the body of a patient suffering from autoimmune disease are provided, comprising contacting the blood or plasma of the patient with an immunoadsorbent having specific binding for an epitope present on germline antibodies, particularly VH4-34 antibodies, wherein said contacting results in the reduction in the amount of germline antibodies present in the blood or bone marrow or lymphoid tissue of the patient or the amount of germline antibody producing B cells present in the blood, lymphoid tissues or bone marrow of the patient. Methods for treating a patient suffering from a B cell cancer expressing cell surface germline antibodies by similar methods are also provided. Methods for ex vivo purging bone marrow of pathologic antibody producing B-cells and cancerous B-cells expressing germline antibodies are provided. Methods for monitoring the efficacy of a therapeutic treatment in a patient suffering from an autoimmune disease or B cell cancer are also provided. Kits and uses in preparation of a medicament are also described.

The invention relates to a cefprozil submicron emulsion solid preparation and new application thereof in the preparation of medicine for treating acute plasma cell mastitis. The cefprozil submicron emulsion granule comprises cefprozil, yolk lecithin, poloxamer 188 and deoxysodium cholate with the weight ratio of 1:2.3-14:1.2-8:0.8-10.

B-cell maturation antigen (BCMA) is expressed on malignant plasma cells. The present invention provides BCMA-specific chimeric antigen receptors and cells expressing such chimeric antigen receptors. In certain embodiments, engineered cells expressing the chimeric antigen receptors of the present invention are capable of inhibiting the growth of tumors expressing BCMA. The engineered cells of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced BCMA-targeted immune response is desired and/or therapeutically beneficial. For example, engineered cells expressing the BCMA-specific chimeric antigen receptors of the invention are useful for the treatment of various cancers, including multiple myeloma.

The present invention discloses a method of applying novel bioinformatics and computational methodologies to data generated by high-resolution genome-wide comparative genomic hybridization and gene expression profiling on CD138-sorted plasma cells from a cohort of 92 newly diagnosed multiple myeloma patients treated with high dose chemotherapy and stem cell rescue. The results revealed that gains the q arm and loss of the p arm of chromosome 1 were highly correlated with altered expression of resident genes in this chromosome, with these changes strongly correlated with 1) risk of death from disease progression, 2) a gene expression based proliferation index, and 3) a recently described gene expression-based high-risk index. Importantly, we also found a strong correlation between copy number gains of 8q24, and increased expression of Argonate 2 (AGO2) a gene coding for a master regulator of microRNA expression and maturation, also being significantly correlated with outcome. Our novel findings significantly improve our understanding of the genomic structure of multiple myeloma and its relationship to clinical outcome.

The present disclosure provides methods for treating allergy comprising selecting a patient with an allergy and administering a therapeutically effective amount of an IL-4/IL-13 pathway inhibitor (e.g., an anti-IL-4 receptor antibody or antigen-binding fragment thereof) in combination with a therapeutically effective amount of an agent that depletes plasma cells (e.g., an anti-BCMA/anti-CD3 bispecific antibody). In certain embodiments, a plasma cell ablating agent such as an anti-BCMA/anti-CD3 bispecific antibody ablates the plasma cells, including IgE+ plasma cells, while the IL-4/IL-13 pathway inhibitor prevents the generation of new IgE+ plasma cells, thus eliminating allergen-specific IgE in the patient.

A method which can isolate plasma cells and plasmablasts efficiently and with high purity, from mammals and birds, without using a cell surface marker is provided.

Further disclosed is a fluorescent probe wherein the staining selectivity for the endoplasmic reticulum of cells is higher than the staining selectivity for cell organelles other than the endoplasmic reticulum. Also disclosed is a method for identifying plasma cells and plasmablasts which includes staining cells derived from lymph node tissue or similar by using this probe, and identifying plasma cells and plasmablasts on the basis of the fluorescence intensity from the stained cells. Also disclosed is a fluorescent probe wherein the staining selectivity for cell nuclei is higher than the staining selectivity for cell organelles other than the cell nuclei. Also disclosed is a method for identifying plasma cells and plasmablasts in lymph node tissue or similar which includes staining cells derived from lymph node tissue or similar by using this probe, and identifying plasma cells and plasmablasts on the basis of the fluorescence intensity from the stained cells.

The present invention provides a hand-held device 10 for providing a flow of plasma for treatment of a treatment region. The device comprises a plasma cell 16 defining a volume in which gas passing through a cell inlet from a gas source 22 can be energised to form a plasma and discharged through a cell outlet for treatment of a treatment region by said generated plasma, and a plurality of electrodes for receiving electrical power for energising gas in the cell to form a plasma, wherein the device comprises a valve arrangement 32 operable in an open condition to allow the discharge of plasma from the device to the treatment region and in a closed condition to resist the passage of ambient contaminants into the device in the absence of gas flow through the device from the gas source.